Pharma News

This section covers the managerial aspects in the Pharma industry.

Hanmi Pharmaceutical Enters into an Exclusive License Agreement with Genentech for a Novel Oral RAF inhibitor

Friday, September 30, 2016

Hanmi Pharmaceutical Co Ltd a Koreabased pharmaceutical company today announced that it has entered into an exclusive development and license agreement with Genentech a member of the Roche Group for the development and commercialization of Hanmis panRAF inhibitor HM95573 which is currently in Phase ..

Zydus and Medicines for Malaria Venture Sign Agreement to Develop Potential New Antimalarial Drug

Friday, September 30, 2016

Zydus Cadila a researchdriven global healthcare provider and Medicines for Malaria Venture MMV announced a collaboration to develop the investigational antimalarial compound MMV674253 Zydus will lead the development of the novel compound and MMV will provide support including scientific expertise an..

Bayer and DelSiTech Partner to Develop Innovative Drug Delivery Technology for Ophthalmology

Friday, September 30, 2016

Bayer and DelSiTech Ltd a Finnish drug delivery technology and drug development company have signed a Collaboration and Technology Licence Agreement for the worldwide application of DelSiTechs Silica Matrix drug delivery platform to a number of Bayers compounds in ophthalmology Successful ocular dr..

Amgen, Arrowhead team up on gene-therapies for heart disease

Friday, September 30, 2016

Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and collaborate with the company to develop genesilencing therapies for heart disease Arrowhead will get 35 million up front and a 215 million injection from Amgen that will give the world39s No 1 biotech company by ma..

Evotec Enters into Strategic Multi-Target Alliance with C4X Discovery

Thursday, September 29, 2016

Evotec AG announced a multitarget collaboration with C4X Discovery Holdings plc C4XD The new agreement builds on the successful research collaboration with C4XD announced in January 2015 and will see C4XD and Evotec work together to develop new small molecule drugs across a range of targets therapeu..

FDA approves expanded use of Vertex Pharma's cystic fibrosis drug

Thursday, September 29, 2016

Vertex Pharamceuticals Inc said the US Food and Drug Administration expanded the use of its cystic fibrosis drug to treat a new subgroup of patients with the rare genetic disorder The company however cut its 2016 sales forecast for the drug Orkambi sending its shares down as much as 4 percent in af..

Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration

Thursday, September 29, 2016

Zymeworks Inc a clinicalstage biopharmaceutical company discovering and developing innovative multifunctional proteinbased therapeutics including bispecific antibodies and drug conjugates for the treatment of cancer and Daiichi Sankyo Company Limited hereafter Daiichi Sankyo announced today that the..

Pfizer Completes Acquisition of Medivation

Thursday, September 29, 2016

Pfizer Inc announced the successful completion of its acquisition of Medivation Inc As of the tender offer expiration 115574041 shares of Medivation common stock were validly tendered representing approximately 691 of the shares outstanding and have been accepted for payment under the terms of the t..

Amgen's multiple myeloma drug falls short in new-patient study

Wednesday, September 28, 2016

Amgen Inc said on Tuesday its multiple myeloma drug Kyprolis did not fare better than Takeda Pharmaceutical Co Ltd39s older therapy Velcade in a study involving patients who had not yet been treated for the disease The US Food and Drug Administration has already approved Kyprolis for patients with ..

Cambrex to Acquire PharmaCore Inc., to Expand Clinical Stage API Capabilities

Wednesday, September 28, 2016

Cambrex Corporation a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients APIs today announced that it has agreed to acquire PharmaCore Inc a privatelyowned company specializing in developing manufacturing and scaling up small molecule APIs for clinical pha..

Bristol-Myers to test Opdivo with Nektar drug for several cancers

Wednesday, September 28, 2016

BristolMyers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers Opdivo which competes with Merck Co39s Keytruda belongs to a costly new class of medicines cal..

Cerecor Announces Acquisition of TARP-γ8-AMPA Receptor Antagonist (CERC-611) from Lilly

Tuesday, September 27, 2016

Cerecor Inc a clinicalstage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders today announced that it has acquired exclusive worldwide rights from Eli Lilly and Company Lilly to develop and commercialize LY313041..

FDA approves J&J's autoimmune drug Stelara for Crohn's disease

Tuesday, September 27, 2016

Johnson Johnson said on Monday that the US Food and Drug Administration approved the company39s blockbuster psoriasis drug Stelara for use in adults with Crohn39s disease The drug is approved in the United States to treat the skin condition scaly plaque psoriasis and a type of arthritis associated..

Sanofi may win U.S. approval of $3 billion eczema drug by March

Tuesday, September 27, 2016

French drugmaker Sanofi and its US partner Regeneron Pharmaceuticals REGNO could win US approval for their keenly awaited new eczema drug dupilumab seen by analysts as a potential 3 billionayear seller by next March Sanofi badly needs new products to make up for flagging sales in its diabetes busin..

Kite immunotherapy drug helps blood cancer patients in study

Tuesday, September 27, 2016

Kite Pharma Inc on Monday said its experimental CAR Tcell therapy which helps the immune system fight cancer was highly effective in treating aggressive nonHodgkin lymphoma although two deaths were related to the drug according to interim data from a midstage trial Shares of Kite which had been hal..

Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

Monday, September 26, 2016

Regeneron Pharmaceuticals Inc and Sanofi today announced that the US Food and Drug Administration FDA has accepted for priority review the Biologics License Application BLA for dupilumab for the treatment of adult patients with inadequately controlled moderatetosevere atopic dermatitis AD a serious ..

Marksans Pharma gets USFDA clearance for allergy drug

Monday, September 26, 2016

Marksans Pharma has received approval from the US health regulator for loratadine liquid filled capsules used for treatment of allergies in the American market In a BSE filing today Marksans Pharma said USFDA has granted approval for an abbreviated new drug application ANDA for loratadine liquid fi..

Ildong Pharma to launch new Hepatitis B drug next year

Monday, September 26, 2016

Ildong Pharmaceuticals Hepatitis B treatment Besifovir is in the process of receiving the Ministry of Food and Drug Safetys approval for sales according to industry sources on Sept 26 It will be the first new drug to be developed by the South Korea pharmaceutical company to be introduced next year ..

FDA approves Amgen's copy of AbbVie arthritis drug Humira

Saturday, September 24, 2016

The US Food and Drug Administration on Friday approved Amgen Inc39s biosimilar version of AbbVie39s topselling arthritis drug Humira The drug Amjevita known also as adalimumabatto was approved to treat rheumatoid arthritis psoriatic arthritis Crohn39s disease psoriasis and other conditions Amjevit..

Novartis's Zykadia gets positive results, faces Roche pressure

Saturday, September 24, 2016

Novartis39s Zykadia drug performed well against a rare form of lung cancer the Swiss company said on Friday citing a study it hopes will help it win expanded regulatory approval for the use of the drug But it faces competition from a medicine produced by rival Roche that some analysts say may alrea..

TOP